Genentech, Inc.

Location not on file

OncologyantibodyGrant-onlyListed · RHHBY

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Study registered, no phase assigned: Clinical Observational Studies:Integrative TCM and Western Medicine for Breast Cancer

11mo agoTrial registeredJul 31, 2025Source filing (opens the source filing in a new tab)

Momentum

64no change

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Grant-only

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Patent
Patent granted
Jan 7, 2025
assignee: Genentech, Inc. · MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF
USPTO · US 12187816 (opens the source filing in a new tab)
Grant
R01 · $669k · non-dilutive
Sep 18, 2024
BAYLOR COLLEGE OF MEDICINE · PI WU, HUAIZHU · NIDDK · award ends May 31, 2029 · MICRORNA REGULATION OF ADIPOSE TISSUE IMMUNE RESPONSE IN OBESITY
NIH RePORTER · NIH RePORTER 11194476 (opens the source filing in a new tab)
Grant
R01 · $622k · non-dilutive
Aug 12, 2024
UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI DEIVANAYAGAM, CHAMPION CHRISTDOSS SELVAKUMAR · NIDCR · award ends May 31, 2029 · Structural and Functional Studies on the Glucosyltransferases of the Dental Caries Pathogen Streptococcus mutans
NIH RePORTER · NIH RePORTER 11167778 (opens the source filing in a new tab)
Grant
R01 · $543k · non-dilutive
Jul 19, 2024
BOSTON CHILDREN'S HOSPITAL · PI WU, HAO · NIAID · award ends May 31, 2029 · Armed nanobodies as anti-infectives and anti-tumor agents
NIH RePORTER · NIH RePORTER 11141686 (opens the source filing in a new tab)
Grant
R01 · $890k · non-dilutive
Mar 8, 2024
BOSTON CHILDREN'S HOSPITAL · PI WU, HAO · NIAID · award ends Jan 31, 2029 · Elucidating structural and functional mechanisms of pyroptosis
NIH RePORTER · NIH RePORTER 11052663 (opens the source filing in a new tab)
Trial
Study registered
Jan 1, 2024
Breast Cancer · RECRUITING · sponsor: Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation · Clinical Observational Studies:Integrative TCM and Western Medicine for Breast Cancer
ClinicalTrials.gov · NCT07096180 (opens the source filing in a new tab)
Grant
R01 · $708k · non-dilutive
May 26, 2023
BOSTON CHILDREN'S HOSPITAL · PI WU, HAO · NIAID · award ends Apr 30, 2028 · Elucidating the functional mechanism of NLRP3 inflammasome activation
NIH RePORTER · NIH RePORTER 11041081 (opens the source filing in a new tab)
Grant
R01 · $638k · non-dilutive
Sep 6, 2022
UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WU, HOLDEN H · NIBIB · award ends Jun 30, 2027 · New Technologies for Real-Time MRI-Guided Robotic-Assisted Abdominal Interventions
NIH RePORTER · NIH RePORTER 11132687 (opens the source filing in a new tab)
Grant
T90 · $344k · non-dilutive
Jul 1, 2021
OREGON HEALTH & SCIENCE UNIVERSITY · PI WU, HUI · NIDCR · award ends Jun 30, 2026 · PORT (Portland Oral health Research Training)
NIH RePORTER · NIH RePORTER 11125905 (opens the source filing in a new tab)
Grant
R90 · $206k · non-dilutive
Jul 1, 2021
OREGON HEALTH & SCIENCE UNIVERSITY · PI WU, HUI · NIDCR · award ends Jun 30, 2026 · PORT (Portland Oral health Research Training)
NIH RePORTER · NIH RePORTER 11125996 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
new_entity links the patent record at 0.50name similarity 100%

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Study registered, no phase assigned: Clinical Observational Studies:Integrative TCM and Western Medicine for Breast Cancer
11mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Clinical Observational Studies:Integrative TCM and Western Medicine for Breast Cancer
11mo agoTrial recruitingSource (opens the source filing in a new tab)
NIH T90 · $0.3M · PORT (Portland Oral health Research Training)
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH R90 · $0.2M · PORT (Portland Oral health Research Training)
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.6M · New Technologies for Real-Time MRI-Guided Robotic-Assisted Abdominal Interventions
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.7M · MICRORNA REGULATION OF ADIPOSE TISSUE IMMUNE RESPONSE IN OBESITY
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.7M · Elucidating the functional mechanism of NLRP3 inflammasome activation
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.5M · Armed nanobodies as anti-infectives and anti-tumor agents
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.9M · Elucidating structural and functional mechanisms of pyroptosis
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.6M · Structural and Functional Studies on the Glucosyltransferases of the Dental Caries Pathogen Streptococcus mutans
May 2025Grant renewalSource (opens the source filing in a new tab)
Patent granted · MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF
Jan 2025Patent grantedSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

Patent granted

R01 · $669k · non-dilutive

R01 · $622k · non-dilutive

R01 · $543k · non-dilutive

R01 · $890k · non-dilutive

Study registered

R01 · $708k · non-dilutive

R01 · $638k · non-dilutive

T90 · $344k · non-dilutive

R90 · $206k · non-dilutive